Therapeutic potential of GLP-1 agonists for hidradenitis suppurativa
Int J Dermatol
.
2023 Dec;62(12):1543-1544.
doi: 10.1111/ijd.16892.
Epub 2023 Oct 28.
Authors
Tanya Henry
1
,
Brian Cahn
2
,
Roger Haber
2
,
John T Landers
3
,
Reed Berger-Fleishman
4
,
Murad Alam
5
,
Sheryl Hoyer
2
Affiliations
1
University of Illinois, College of Medicine, Chicago, IL, USA.
2
Department of Dermatology, University of Illinois, Chicago, IL, USA.
3
Lovell Federal Health Care Center, North Chicago, IL, USA.
4
Department of Bariatric Surgery, University of Illinois, Chicago, IL, USA.
5
Department of Dermatology, Northwestern Medicine, Chicago, Illinois, USA.
PMID:
37897079
DOI:
10.1111/ijd.16892
No abstract available
MeSH terms
Glucagon-Like Peptide 1* / therapeutic use
Glucagon-Like Peptide-1 Receptor* / agonists
Hidradenitis Suppurativa* / drug therapy
Humans
Substances
Glucagon-Like Peptide 1
Glucagon-Like Peptide-1 Receptor